Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

A legfontosabb adatok

Ki végzi
Janssen Research & Development, LLC
Hol
Austin, Avon, Boston, Chicago, Cincinnati, Cleveland, Durham, Hackensack, Hickory, New Hyde Park, Philadelphia, Portland, Salt Lake City és San Diego (Egyesült Államok)Mind a 14 helyszín megnézéseMég 8 másik országban, 24 helyszínen
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
130 fő vett részt
Kezdés
2014. dec. 22.
Befejezés
2024. szept. 27.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Golimumab
  • Methotrexate
A regiszteradat frissítve
2025. november 14.

Ki vehet részt

Életkor
2 év – 17 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 11 feltétel megnézéseKevesebb

Ki vehet részt

  • Diagnosis must be made per Juvenile Idiopathic Arthritis (JIA) International League of Associations for Rheumatology (ILAR) diagnostic criteria and the onset of disease must have been before the participant's 16th birthday
  • Failure or inadequate response to at least a 2 month course of methotrexate (MTX) before screening
  • Participants must have greater than or equal to (>=) 5 joints with active arthritis at screening and at Week 0 as defined by American College of Rheumatology (ACR) criteria (that is, a joint with either swelling, or in the absence of swelling, limited range of motion associated with pain on motion or tenderness)
  • Participants must have a screening C-reactive protein (CRP) of >=0.1 milligram (mg)/deciliter (dL) with the exception of approximately 30 percent (%) of the study population
  • Participants must have active polyarticular juvenile idiopathic arthritis (pJIA) despite current use of oral, intramuscular, or subcutaneous MTX for >=2 months before screening. For participants with body surface area (BSA) less than (<)1.67 meter square (m\^2), the MTX dose must be between 10 to 30 milligram per meter square (mg/m\^2) per week and stable for >=4 weeks before screening. For participants with BSA >=1.67 m\^2, the MTX dose must be a minimum of 15 mg/week and must be stable for >=4 weeks before screening. In situations where there is documented intolerance of doses greater than (>)10 mg/m\^2 weekly (for participants with BSA <1.67 m\^2) or >=15 mg/week (for participants with BSA >=1.67 m\^2); or where documented country or site regulations prohibit use of >=15 mg of MTX per week in participants with BSA >=1.67 m\^2, participants may be entered into the trial on a lower dose of MTX

Ki nem vehet részt

  • Participant has initiated disease-modifying antirheumatic drugs (DMARDs) and/or immunosuppressive therapy within 4 weeks prior to first study agent administration
  • Participant has been treated with intra-articular, intramuscular or intravenous corticosteroids (including intramuscular corticotropin) during the 4 weeks before first study agent administration
  • Participant has been treated with any therapeutic agent targeted at reducing Interleukin (IL)-12 or IL 23, including but not limited to ustekinumab and ABT-874, within 3 months before first study agent administration
  • Participant has been treated with alefacept within 3 months before first study agent administration
  • If a participant has been previously treated with an anti-tumor necrosis factor alpha (TNF alpha) agent, the reason for discontinuation of the anti-TNF alpha agent cannot have been a severe or serious adverse event consistent with the class of anti-TNF alpha agents
  • Participant has been treated with natalizumab, efalizumab, or therapeutic agents that deplete B or T cells (eg, rituximab, alemtuzumab, or visilizumab) during the 12 months before first study agent administration, or have evidence at screening of persistent depletion of the targeted lymphocyte after receiving any of these agents

Helyszínek itt: Egyesült Államok

Még 8 másik országban, 24 helyszínen

  • Austin, TexasHospital not named in the registry
  • Avon, OhioHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Chicago, IllinoisHospital not named in the registry
  • Cincinnati, OhioHospital not named in the registry
  • Cleveland, OhioHospital not named in the registry
  • Durham, North CarolinaHospital not named in the registry
  • Hackensack, New JerseyHospital not named in the registry
  • Hickory, North CarolinaHospital not named in the registry
  • New Hyde Park, New YorkHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Portland, OregonHospital not named in the registry
  • Salt Lake City, UtahHospital not named in the registry
  • San Diego, CaliforniaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) of golimumab administered intravenously (IV) to pediatric participants with polyarticular (affects 5 or more joints) juvenile (an onset before age 16) idiopathic (of unknown cause) arthritis (joint pain) (pJIA) manifested by greater than or equal to (>=) 5 joints with active arthritis despite methotrexate (MTX) therapy for >= 2 months.

A vizsgálat csoportja

  • Golimumab + MethotrexateA vizsgált kezelés

    Participants will receive 80 milligram per meter square (mg/m\^2) as an intravenous (IV) infusion at Weeks 0, 4, and every 8 weeks thereafter up to Week 244, along with commercial methotrexate (MTX) weekly through Week 28 at the same Body Surface Area (BSA)-based dosage (10 to 30 mg/m\^2 per week for participants with BSA less than \[\<\] 1.67 meter square (m\^2), or minimum of 15 mg/week for participants with BSA greater than or equal to \[\>=\] 1.67 m\^2) as at the time of study entry. At Week 252, participants who meet the criteria for the optional Extended Treatment Period (ETP) may continue treatment with golimumab 80 mg/m\^2 every 8 weeks after completion of the Week 252 assessments.

    Kezelés: Golimumab és Methotrexate

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
Publikációk
A regiszteradat frissítve
2025. november 14.